Tabriz University of Medical Sciences BioImpacts 2228-5652 15 1 2025 01 19 CAR-T cell therapy as an approach for pediatric hematological malignancies in regenerative therapy: Current status and clinical outcomes 31459 31459 10.34172/bi.31459 EN Xiaoman Guo https://orcid.org/0009-0009-7600-6779 Xueyin Jiang https://orcid.org/0009-0001-3621-5615 Juan Zhang https://orcid.org/0009-0007-2915-8185 Journal Article 10.34172/bi.31459 2025 06 11 2025 08 18 Radiation therapy, chemotherapy, and surgery have been the standard cancer treatment approaches for many years. Even with these treatments, the majority of tumors still have a dismal prognosis. With complete remission rates ranging from 65% to 90% in the crucial CD19-CART trials, chimeric antigen receptor T-cell (CART) therapy has revolutionized the treatment paradigm for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Hematological tumors have responded well to CART. The first CART was authorized by the FDA in 2017 to treat B-ALL. The FDA authorized CART to treat B-cell lymphoma in October of that year. In recent years, research has focused on CART to increase and improve the therapeutic effect. New toxicity profiles and treatment constraints have also surfaced with this new medicine, calling for cooperative group trials, new management strategies, and toxicity consensus grading systems. The introduction of CART treatment for pediatric B-cell ALL will be the main topic of this article, along with previous and ongoing trials. We will also talk about CART therapy trials for various pediatric cancers. Safe procedures and close observation are essential since CART treatment has the potential to cause serious toxicities.